RETROVIR by GSK is [see microbiology ()] . Approved for maternal-fetal hiv-1 transmission [see dosage, administration ()], combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 1990.
Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
RETROVIR (zidovudine) is a nucleoside reverse transcriptase inhibitor (NRTI) used to treat human immunodeficiency virus (HIV) infection. It works by inhibiting reverse transcriptase, an enzyme critical for HIV replication. This small-molecule antiviral was the first FDA-approved HIV treatment and remains a foundational component in some combination regimens.
This legacy product faces significant competitive pressure (30%) and approaching loss of exclusivity, indicating minimal growth opportunity and likely reduced team size on brand initiatives.
[see Microbiology ()] .
Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)
A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood
A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection
A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)
Worked on RETROVIR at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on RETROVIR offers limited growth and advancement opportunities given its LOE-approaching status and minimal commercial investment. Pharma professionals on this product should expect defensive market management, geographic specialty focus (e.g., resource-limited settings, maternal health programs), and potential organizational restructuring as the franchise winds down.